Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity

• DOI: 10.1016/j.ejca.2020.10.006
• Publication Date: 2020-11-10T18:04:00Z
• Authors: Luca Mazzarella; Silvia Giugliano; Paolo D'Amico; Carmen Belli; Bruno Achutti Duso; Maria Rescigno; Giuseppe Curigliano
• Keywords: Male; IL17; Interleukin-17; Mesothelioma, Malignant; Middle Aged; IL17; Immune-related adverse event; Immunotherapy; Myasthenia gravis; PD1; Antineoplastic Agents, Immunological; Autoimmune Hypophysitis; Diabetes Mellitus, Type 1; Fatal Outcome; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Interleukin-17; Male; Mesothelioma, Malignant; Middle Aged; Myasthenia Gravis; 3. Good health; PD1; 03 medical and health sciences; Antineoplastic Agents, Immunological; Diabetes Mellitus, Type 1; Fatal Outcome; 0302 clinical medicine; Immune-related adverse event; Myasthenia Gravis; Humans; Autoimmune Hypophysitis; Immunotherapy; Myasthenia gravis; Immune Checkpoint Inhibitors

Severe neurological and endocrine toxicities are well recognised adverse events of immune checkpoint inhibitors. However, the underlying pathophysiology is poorly understood, and classical circulating markers are often non-informative, making it difficult to obtain a precise diagnosis and to initiate timely and effective treatment. Here we investigated immune-modulating activity in the plasma of a mesothelioma patient who developed fatal neuroendocrine toxicity characterised by insulin-dependent diabetes, hypophisitis and a myasthenia-like syndrome while on treatment with the dual PD1 and TIM3 blockade.We used an in vitro functional assay for unbiased detection of plasma dendritic cell-modulating activity, followed by cytokine quantification by the Cytokine Bead Array.Immunosuppressive treatment as per established guidelines could not prevent the fatal outcome. Patient's plasma contained a dendritic cell-stimulating activity that induced specific markers (CD25+) compatible with T-helper 17 stimulation. Consistently, elevated levels of interleukin 17 (IL17A), but no other cytokines, were identified in the patient's plasma but not in controls (healthy volunteers and patients treated with immunotherapy without neuroendocrine toxicities).If confirmed in larger series, these data suggest IL17 as a candidate diagnostic and therapeutic target in the management of high-grade neuroendocrine immune-related adverse events.